Remepy, a New York-based hybrid medicine developer, closed a $10M seed funding spherical, which, along with earlier funding, totalled $15M.
The spherical was led by NFX, joined by Vine Ventures, PsyMed Ventures, Supernode Ventures and Firstime Ventures, becoming a member of earlier pre-seed lead investor TechAviv in addition to Contemporary.fund, Samsung Subsequent, StageNext Fund and 97212 Ventures.
Led by Dr. Michal Tsur, and Or Shoval, Remepy is pioneering Hybrid Medicine, that are conventional medicine mixed with digital therapeutics which might be personalised and improve the impact of pharmaceutical remedies. Digital molecules are therapeutic interventions that set off physiological results (aka MOAs, Mechanisms of Motion) by way of the mind. These physiological adjustments have been identified to boost the effectiveness of conventional medicine.
The corporate has already confirmed in human research the impact of its merchandise, utilizing intensive mind imaging, in addition to blood and saliva samples, with promising outcomes for Oncology, MCI, and Parkinson’s Illness.
Remepy is concentrating on neurodegenerative ailments, most cancers, autoimmune ailments, and degenerative eye ailments.
FinSMEs
01/05/2024
